Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/17993 |
Resumo: | PURPOSE: This study aimed to evaluate the efficacy of the systemic drugs thalidomide, dapsone, colchicine, and pentoxifylline in the treatment of severe manifestations of RAS. METHODS: An open, 4-year clinical trial was carried out for 21 consecutive patients with severe RAS. Initially, patients were given a 2-week course of prednisone to bring them to a baseline status. Simultaneously, one of the four test drugs was assigned to each patient to be taken for a period of 6 months. During the course of the trial, patients were switched to one of the other three drugs whenever side effects or a lack of satisfactory results occurred, and the 6-month limit of the treatment was then reset. RESULTS: The most efficient and best-tolerated drug was thalidomide, which was administered to a total of eight patients and resulted in complete remission in seven (87.5%). Dapsone was prescribed for a total of nine patients, of whom eight (89%) showed improvement in their symptoms, while five showed complete remission. Colchicine was administered to a total of ten patients, with benefits observed in nine (90%), of whom four showed complete remission. Pentoxyfilline was administered to a total of five patients, with benefits observed in three (60%), of whom one patient showed complete remission. CONCLUSION: The therapeutic methods used in this trial provided significant symptom relief. Patients experienced relapses of the lesions; however, this occurred after withdrawal of their medication during the follow-up period. |
id |
USP-19_14a9b5c1a67c34690ce5eae964b8fad1 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/17993 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial Aphthous stomatitisThalidomideColchicinePentoxyfillineDapsone PURPOSE: This study aimed to evaluate the efficacy of the systemic drugs thalidomide, dapsone, colchicine, and pentoxifylline in the treatment of severe manifestations of RAS. METHODS: An open, 4-year clinical trial was carried out for 21 consecutive patients with severe RAS. Initially, patients were given a 2-week course of prednisone to bring them to a baseline status. Simultaneously, one of the four test drugs was assigned to each patient to be taken for a period of 6 months. During the course of the trial, patients were switched to one of the other three drugs whenever side effects or a lack of satisfactory results occurred, and the 6-month limit of the treatment was then reset. RESULTS: The most efficient and best-tolerated drug was thalidomide, which was administered to a total of eight patients and resulted in complete remission in seven (87.5%). Dapsone was prescribed for a total of nine patients, of whom eight (89%) showed improvement in their symptoms, while five showed complete remission. Colchicine was administered to a total of ten patients, with benefits observed in nine (90%), of whom four showed complete remission. Pentoxyfilline was administered to a total of five patients, with benefits observed in three (60%), of whom one patient showed complete remission. CONCLUSION: The therapeutic methods used in this trial provided significant symptom relief. Patients experienced relapses of the lesions; however, this occurred after withdrawal of their medication during the follow-up period. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2009-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1799310.1590/S1807-59322009000300008Clinics; Vol. 64 No. 3 (2009); 193-198 Clinics; v. 64 n. 3 (2009); 193-198 Clinics; Vol. 64 Núm. 3 (2009); 193-198 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/17993/20058Mimura, Maria Angela MartinsHirota, Silvio KenjiSugaya, Norberto NobuoSanches Jr, José AntonioMigliari, Dante Antonioinfo:eu-repo/semantics/openAccess2012-05-22T18:50:10Zoai:revistas.usp.br:article/17993Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-22T18:50:10Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial |
title |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial |
spellingShingle |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial Mimura, Maria Angela Martins Aphthous stomatitis Thalidomide Colchicine Pentoxyfilline Dapsone |
title_short |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial |
title_full |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial |
title_fullStr |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial |
title_full_unstemmed |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial |
title_sort |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial |
author |
Mimura, Maria Angela Martins |
author_facet |
Mimura, Maria Angela Martins Hirota, Silvio Kenji Sugaya, Norberto Nobuo Sanches Jr, José Antonio Migliari, Dante Antonio |
author_role |
author |
author2 |
Hirota, Silvio Kenji Sugaya, Norberto Nobuo Sanches Jr, José Antonio Migliari, Dante Antonio |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Mimura, Maria Angela Martins Hirota, Silvio Kenji Sugaya, Norberto Nobuo Sanches Jr, José Antonio Migliari, Dante Antonio |
dc.subject.por.fl_str_mv |
Aphthous stomatitis Thalidomide Colchicine Pentoxyfilline Dapsone |
topic |
Aphthous stomatitis Thalidomide Colchicine Pentoxyfilline Dapsone |
description |
PURPOSE: This study aimed to evaluate the efficacy of the systemic drugs thalidomide, dapsone, colchicine, and pentoxifylline in the treatment of severe manifestations of RAS. METHODS: An open, 4-year clinical trial was carried out for 21 consecutive patients with severe RAS. Initially, patients were given a 2-week course of prednisone to bring them to a baseline status. Simultaneously, one of the four test drugs was assigned to each patient to be taken for a period of 6 months. During the course of the trial, patients were switched to one of the other three drugs whenever side effects or a lack of satisfactory results occurred, and the 6-month limit of the treatment was then reset. RESULTS: The most efficient and best-tolerated drug was thalidomide, which was administered to a total of eight patients and resulted in complete remission in seven (87.5%). Dapsone was prescribed for a total of nine patients, of whom eight (89%) showed improvement in their symptoms, while five showed complete remission. Colchicine was administered to a total of ten patients, with benefits observed in nine (90%), of whom four showed complete remission. Pentoxyfilline was administered to a total of five patients, with benefits observed in three (60%), of whom one patient showed complete remission. CONCLUSION: The therapeutic methods used in this trial provided significant symptom relief. Patients experienced relapses of the lesions; however, this occurred after withdrawal of their medication during the follow-up period. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/17993 10.1590/S1807-59322009000300008 |
url |
https://www.revistas.usp.br/clinics/article/view/17993 |
identifier_str_mv |
10.1590/S1807-59322009000300008 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/17993/20058 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 64 No. 3 (2009); 193-198 Clinics; v. 64 n. 3 (2009); 193-198 Clinics; Vol. 64 Núm. 3 (2009); 193-198 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222754426847232 |